GeneDx Holdings Corp. (WGS)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.57B
Last updated: Nov 17, 2026 at 11:05 AM ET
GeneDx Holdings Corp. (WGS) Stock Forecast
Analysts expect GeneDx Holdings (WGS) to earn $0.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $478.02M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 7 | 87.5% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 972.7% and revenue estimates rise 21.9%.
- Fiscal year ending Dec 31, 2026
- $0.11
- EPS consensus, revenue $478.02M
- Fiscal year ending Dec 31, 2027
- $1.18
- EPS consensus, revenue $582.90M
- Next report
- Feb 22, 2027
- Confirmed, after the close
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.11 | $0.02 to $0.22 | 4 | $478.02M | $474.90M to $483.40M | 9 |
| Dec 31, 2027 | $1.18 | $0.44 to $2.00 | 5 | $582.90M | $543.70M to $611.00M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.41 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.41 | $0.37 to $0.53 | 9 | $137.43M | $130.14M to $149.52M | 9 |
| Mar 31, 2027 | -$0.01 | -$0.16 to $0.10 | 3 | $122.87M | $115.30M to $130.70M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 7 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 2 |
| Fiscal year ending Dec 31, 2027 | 5 | 3 |
| Quarter ending Mar 31, 2027 | 2 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 15.4% from $0.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.11 | $0.13 | $0.13 | $0.13 | $0.13 | -15.7% |
| Fiscal year ending Dec 31, 2027 | $1.18 | $1.20 | $1.20 | $1.17 | $1.17 | +1.0% |
| Quarter ending Mar 31, 2027 | -$0.01 | $0.04 | $0.04 | $0.06 | $0.06 | N/A |
Frequently Asked Questions About WGS
What is the WGS stock forecast?
Consensus analyst estimates put GeneDx Holdings's EPS at $0.11 for the fiscal year ending Dec 31, 2026, on revenue of $478.02M. The consensus rating from 8 analysts is Buy.
How do analysts rate WGS stock?
Of 8 analysts covering GeneDx Holdings, 1 rates it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from WGS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.11, with estimates from $0.02 to $0.22 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.18, with estimates from $0.44 to $2.00 from 5 analysts.
What revenue do analysts expect from GeneDx Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $478.02M, with estimates from $474.90M to $483.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $582.90M, with estimates from $543.70M to $611.00M.
How many analysts cover WGS?
8 analysts rate GeneDx Holdings stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
WGS pages: Overview, Earnings, Forecast, Financials, Valuation